相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas
Bruce D. Cheson et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
PI3K inhibitors and the search for the Holy Grail
Ian W. Flinn
BLOOD (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition
Philip Earwaker et al.
PLOS ONE (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Ian W. Flinn et al.
BLOOD (2018)
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
Anas Younes et al.
HAEMATOLOGICA (2017)
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Martin Dreyling et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
Anas Younes et al.
HAEMATOLOGICA (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
K. Balakrishnan et al.
LEUKEMIA (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming
Veronica Martinez-Marignac et al.
Oncotarget (2015)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
G. S. Ducker et al.
ONCOGENE (2014)
The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro
Lilian Amrein et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma
Oussama M. Darwish et al.
UROLOGY (2013)
Pharmacological targeting of eIF4E in primary CLL lymphocytes
V. Martinez-Marignac et al.
BLOOD CANCER JOURNAL (2013)
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ -Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse
Sunil Iyengar et al.
BLOOD (2012)
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients
Jonathan Hebb et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
Matthias Niedermeier et al.
BLOOD (2009)
分享论文
